Despite two ongoing clinical trials on the use of plasma therapy for COVID-19 patients and the recent regulations allowing off-label (outside clinical trials) use of convalescent plasma for emergency cases, it is not a popular option in city hospitals. While doctors described challenges like lack of availability of viable plasma and the need for more clarity on treatment protocol, civic officials feel that most private hospitals don't opt for plasma therapy as it is low-cost.

The two ongoing clinical trials on plasma therapy include the PLACID trial started by the ICMR and the state's Project Platina. Given the growing number of COVID-related deaths in the state, on June 29, the Directorate of Medical Education and Research (DMER) allowed off-label use of plasma therapy to patients with moderate symptoms but not responding to medication. While no approvals are needed for off-label use, private hospitals opting for it have to inform the state government and the Drug Controller General of India.